echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Chuangsheng Group completed the first patient administration of Claudin 18.2 monoclonal antibody TST001 Phase IIa trial

    Chuangsheng Group completed the first patient administration of Claudin 18.2 monoclonal antibody TST001 Phase IIa trial

    • Last Update: 2021-08-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Chuangsheng Group announced that the first patient in the phase IIa clinical trial of TST001 has successfully completed the administration on August 17


    Claudin 18.


    Chuangsheng Group launched a phase I clinical trial of TST001 in the United States and China in August 2020, led by Professor Lin Shen from Peking University Cancer Hospital, to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TST001


    The Phase IIa clinical trial of TST001 is an open, single-arm, multi-center study, which aims to further evaluate the safety, tolerability, and anti-tumor efficacy of TST001 in patients with multiple solid tumors expressed by Claudin 18.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.